Patients with hormone-refractory prostate cancer
Conditions
Sponsors
University Hospital Motol
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Histological confirmed prostatic adenocarcinoma Progression of PSA serum concentration after the failure of second line hormonal therapy in generalized disease Karnofsky performance status more than 80% Signed informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: HIV positivity, active B or C hepatitis Severe cardiac or other internal disease limiting patient survival History of primary immunodeficiency, active autoimmunity requiring tratment or anaphylactic reaction after previous vaccination Negative informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Safety and toxicity;Secondary Objective: Immunological and biochemical responses;Primary end point(s): Evaluation of adverse reaction to the vaccination with DC, immunological and biochemical response to vaccine | — |
Countries
Czech Republic
Outcome results
None listed